Status:
COMPLETED
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Alzheimer Disease
Mild Cognitive Impairment
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
Novel blood-based biomarkers of Alzheimer's disease (AD), such as plasma levels of tau phosphorylated at threonine 181 (p-tau181), have shown great promise in detecting early AD pathology. While curre...
Detailed Description
Novel blood-based biomarkers of Alzheimer's disease (AD), such as plasma levels of tau phosphorylated at threonine 181 (p-tau181), have shown great promise in sensitively and specifically detecting ea...
Eligibility Criteria
Inclusion
- Participants recruited will include 62 adults aged 60 and older.
- Consensus diagnosis of amnestic MCI by Vanderbilt Alzheimer's Disease Research Center (VADRC) clinician panel.
- Availability of a reliable study partner (reliable is defined as someone who interacts significantly with the participant and is available to participate in study visits in person).
- English language fluency.
Exclusion
- Individuals who lack decisional capacity to provide informed consent at baseline will not be enrolled in the study.
- History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., epilepsy, multiple sclerosis, Parkinson's disease), or head injury with significant loss of consciousness.
- Presence of acute psychological distress (i.e., Geriatric Depression Scale \>10 at screening).
- Participation in other risk disclosure protocols.
Key Trial Info
Start Date :
September 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2025
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT05377060
Start Date
September 1 2022
End Date
June 1 2025
Last Update
June 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Illinois, United States, 37212